US FDA’s Record Year For Drug Approvals? Wall Street Is Unimpressed
Executive SummaryPace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels.
You may also be interested in...
Celgene has been vilified in the political realm for excessive price increases, which hasn’t helped its stock performance over past year and a half.